长春西汀对慢性阻塞性肺疾病大鼠炎症干预作用的探讨

Effect of vinpocetine on inflammation in rats with chronic obstructive pulmonary disease

目的 探讨长春西汀对慢性阻塞性肺疾病（COPD）慢性炎症的作用.方法 将40只雄性Wistar大鼠随机分为正常对照组、COPD模型组、长春西汀5 mg/kg组、2.5 mg/ks组和1.25 mg/ks组,每组8只.采用熏香烟加气管内注入脂多糖法建立COPD大鼠模型.长春西汀组（共3组）从注入脂多糖次日起给予长春西汀腹腔注射,每日1次.观察各组大鼠肺组织病理改变,检测血清中肿瘤坏死因子（TNr）-a、白细胞介素（IL）-8、C反应蛋白（CRP）的浓度以及支气管肺泡灌洗液（BALF）中TNF-a、IL-8的浓度.结果 COPD模型组肺组织病理改变符合人类COPD的病理特点;长春西汀5 mg/kg组和2.5 mg/kg组病理改变较模型组轻;上述两组血清IL-8浓度分别为（18.40±2.40）和（19.30±3.11）ng/L,比COPD模型组[（23.81±3.54）ns/L]低,血清TNF-a浓度分别为（39.34±3.43）和（40.47±3.09）ns/L,比COPD模型组[（46.65±4.42）ns/L低],血清CRP浓度分别为（4.28±0.22）和（4.35±O.26）ms/L,比COPD模型组[（4.69±0.19）ms/L]低;上述2组肺泡灌洗液中IL-8浓度分别为（20.09 ±2.88）和（21.03±2.21）ng/L,低于COPD模型组[（25.02±2.92）ng/L],TNF-a浓度分别为（40.41±4.40）和（41.18±5.33）ng/L,低于COPD模型组[（48.81±4.92）ng/L],差异均有统计学意义.长春西汀1.25 mg/ks组各项指标与COPD模型组比较,差异无统计学意义（P〉0.05）.结论 长春西汀能降低COPD大鼠血清和BALF中炎性因子的水平,减轻气道及肺组织炎症,对COPD大鼠的炎症反应有一定的抑制作用.

Objective To observe the effect of vinpecetine on inflammatory factors and lung pathology of the rats with chronic obstructive pulmonary disease（COPD）,and to investigate the therapeutic action of vinpecetine on COPD.Methods Totally 40 Wistar rats were randomly divided into the normal control group,the COPD model group and three viupocetine treated groups.The COPD rat model wag established by intratracheal instillation of lipepalysaceharide and exposure to cigarette smoke.The three intervention groups were intrapedtonealy injected with vinpecetine respectively at the dose of 1.25 mg/kg,2.5 mg/kg and 5 mg/kg before exposing to cigarette smoke.Pathologic changes of the lung tissue,interlukin（IL）-8 and tumor necrosis factor （TNF）-a levels in bronchial alveolarhvage fluid（BALF）and seruln,and CRP level in the serum were determined.Results The pathological changes in the COPD rat model were coincident with the changes in human.Compared with the COPD model group,the two groups treated with vinpecetine at the dose of 2.5 mg/kg and 5 mg/kg showed a significan t decrease in IL-8[（18.40 ±2.40）ng/L,（19.30±3.11）ng/L respectively vs（23.81±3.54）ng/L],TNF-a[（39.34±3.43）ng/L,（40.47±3.09）ns/L respectivelyvs （46.65±4.42）ng/L],and CRP[（4.28±0.22）mg/L,（4.35±0.26）mg/L respectively vs（4.69±0.19）mg/L]in serum.In the BALF of those the BALF of those two groups, the levers of Ⅱ-8[（20.09 4±2.88）ng/L,（21.03±2.21）ng/L]and TNF-a[（40.41±4.40）ng/L,（41.18 4±5.33）ng/L]were also significantly lower than those in the moder group[（25.02±2.92）.g/L,（48.81±4.92）ng/L].The vinpocetine treated group at the dose of 1.25mg/kg ad no significant difference, compared with the COPD model group. Conclusions Vinpocetine can reduce the levels of inflammatory factors in BALF and the serum of the rats with COPD and decrease inflammation of the airway and lung tissue. Accordingly vinpecetine can inhibit the inflammation of the COPD rat model.